Johnson & Johnson's Cardiovascular Business Drives Medtech Growth in 2025 with 15.8% YoY Sales Increase

Johnson & Johnson's cardiovascular business drove strong growth in its medtech sales in 2025, with a 15.8% year-over-year increase to $8.93 billion. The company's electrophysiology unit grew 7% to $5.63 billion, while Abiomed and Shockwave Medical units both topped $1 billion in sales. J&J's medtech sales reached $33.79 billion, a 6.1% growth year over year.